Comment from Boehringer Ingelheim Pharmaceuticals, Inc.

Summary: Boehringer Ingelheim Pharmaceuticals, Inc. provides comments on the draft guidance for Master Protocols for Drug and Biological Product Development. The company supports the general direction of the guidance but suggests specific clarifications regarding sponsor responsibilities, randomization methods for irrational ratios, operational burdens of changing ratios, and the inclusion of control patients in primary analyses.